血培养MSSA,选择万古、利奈还是头孢唑啉?
金葡菌是人类重要的致病菌,是社区与院内获得性菌血症的首要病原菌之一。本文重点探讨 MSSA 血流感染抗菌方案的合理选择。
探讨之前介绍相关术语和一个病例:
MSSA 菌血症首选耐酶青霉素与一代头孢类,万古霉素、利奈唑胺不作为首选;
参考文献
1.Small PM, Chambers HF. Vancomycin for Staphylococcusaureusendocarditisinintravenousdrugusers.AntimicrobAgentsChemother.1990;34:1227–31.
2.Fernandez Guerrero ML, deGorgolasM. Comparative activity of cloxacillinandvancomycinagainst methicillin-susceptible Staphylococcus aureusexperimen-talendocarditis. JAntimicrobChemother.2006;58:1066–9.
3.Liu C, Bayer A, Cosgrove SE,DaumRS,FridkinSK,GorwitzRJ, Kaplan SL,KarchmerAW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF; Infectious Diseases Society of America. Clinical practice guidelines by the infectiousdiseasessociety ofamericafor the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011 Feb 1;52(3):e18-55.
4.LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.AntimicrobAgents Chemother 2004; 48:4665–72.
5.GudiolF,AguadoJM, Almirante B, et al. Diagnosis and treatment ofbacteremia and endocarditis due to Staphylococcus aureus. A clinicalguideline from the SpanishSociety of Clinical Microbiology andInfectious Diseases (SEIMC).EnfermedadesInfeccY MicrobiolClínica.2015;33:625, e1–625.e23
6.John E. Bennett,Raphael Dolin, Martin J. Blaser. Mandell Douglas and Bennett's Principles and Practice of Infectious Diseases, 9th Edition. 2019.
7.NaberC,BaddourL,Giamarellos-BourboulisE, et al. Clinical consensus conference: survey on gram-positive bloodstream infections with a focus on Staphylococcus aureus. Clin Infect Dis. 2009;48: S260–S70.
8.Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditisin intravenous drug users.AntimicrobAgents Chemother1990; 34:122731.
9.StryjewskiME,SzczechLA, Benjamin DK Jr., et al Use of vancomycinor first-generation cephalosporins for the treatment of hemodialysisdependentpatients with methicillin-susceptible Staphylococcus aureusbacteremia. Clin Infect Dis 2007; 44:1906.
10.Chang FY, Peacock JE Jr., Musher DM, et al Staphylococcus aureusbacteremia: recurrence and the impact of antibiotic treatment inaprospectivemulticenterstudy.Medicine(Baltimore)2003;82:3339.
11.Kim SH, Kim KH, Kim HB, et al Outcome of vancomycin treatmentin patients with methicillin-susceptible Staphylococcus aureus bacteremia.AntimicrobAgents Chemother 2008; 52:1927.
12.LodiseTP Jr., McKinnon PS, Levine DP, et al Impact of empiricaltherapyselection on outcomes of intravenous drug users with infectiveendocarditis caused by methicillin-susceptible Staphylococcusaureus.AntimicrobAgents Chemother 2007; 51:37313.
13.Chang F-Y, Peacock JE, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine(Baltimore).2003;82:333–339.
14.McDanelJS,PerencevichEN,DiekemaDJ,HerwaldtLA, Smith TC,ChrischillesEA, Dawson JD, Jiang L,GotoM, Schweizer ML. Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals. Clin Infect Dis. 2015 Aug 1;61(3):361-7.doi: 10.1093/cid/civ308.Epub2015 Apr 21. PMID: 25900170.
15.利奈唑胺药物说明书.